JMAR's Compact X-Ray Microscope Reaches 50 Nanometer Resolution.

SAN DIEGO -- JMAR Technologies, Inc. (OTCBB:JMAR), a leading developer of advanced laser, high resolution imaging and photonics technologies, has successfully hit the 50 nm resolution milestone targeted in the development of its compact soft X-ray Microscope.

JMAR's compact soft X-ray Microscope (XRM) bridges the sizeable gap between optical microscopes, which are typically greater than 200 nm resolution, and transmission electron microscopes that resolve feature sizes as small as 0.1 nm. Key advantages of the XRM include the ability to provide not only 2D images, but full 3D topographic reconstructions of whole cells, without altering the cell structure by slicing. Additionally, soft X-rays provide natural contrast for cell imaging, eliminating the need for staining. This greatly reduces sample preparation time and complexity, as compared to transmission electron microscopy, while still providing high resolution imaging.

"This is a significant milestone in the development of a commercially viable compact soft X-ray microscope. Researchers in the bio and life sciences will be able to do in their own labs what is currently only possible at a few large scale facilities worldwide," said Dr. Oscar Hemberg, General Manager of JMAR's Research Division. "We are very excited over our development progress and the potential for high-resolution, single-cell tomography."

"Advances in nanotechnology, and more specifically soft X-ray microscopy, are paving the way for major breakthroughs in biomedical applications," stated Neil Beer, CEO and president of JMAR. "JMAR's expertise has positioned us on the cutting edge of these developing technologies."

JMAR is completing its first working prototype of the XRM and there is active interest from several companies in partnering on the final development and commercialization of the instrument.

About JMAR Technologies

JMAR Technologies, Inc. is a leading innovator in the development of laser-based technology and X-ray processes for nano-scale imaging, analysis and fabrication. The Company is leveraging more than a decade of laser and photonics research to develop a portfolio of products with commercial applications in rapidly growing industries, while continuing to carry out research and development for the U.S. Government.

JMAR's flagship commercialization product, BioSentry[TM], is a contamination warning system for waterborne microorganisms. BioSentry[TM] uses laser-based, multi-angle light scattering technology to provide continuous, on-line, real-time monitoring for harmful microorganisms. BioSentry[TM] is targeted toward a number of applications across multiple markets, including homeland security, the cruise ship and beverage industries, pharmaceutical companies, and municipal water utilities.

JMAR's pursuit of leading edge products targets nanotechnology, bioscience and the semiconductor industries with its BriteLight[TM] laser, a stand-alone product as well as the X-ray light source in nanolithography systems; the X-ray Microscope for 3D visualization of single cells and polymers; and the X-ray NanoProbe for enabling nano-scale interaction, analysis and materials modification. In addition, JMAR employs key strategic alliances for the production of a hazardous materials chemical sensor, and the prototyping and production of a nanoparticle ultra-thin coating system.

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a number of factors, including the risk that the transition of the trading or quotation of our shares of common stock to the OTC Bulletin Board or to the "Pink Sheets" may have an adverse effect on the price or liquidity of our shares of common stock, including a possible decline in the number of market makers who are willing to make a market in our stock, and our ability to engage in certain financing transactions on terms as favorable as when the Company's shares were traded on The Nasdaq Stock Market, the performance validation tests of the BioSentry Beta units are not successfully completed due to unforeseen issues with the installation and operation of the units outside of the controlled environment of JMAR's facility, delays in completion of the X-ray Microscope and X-ray NanoProbe prototypes and transition to production units, the failure of the technology to perform as predicted, competition from alternative technologies, uncertainties as to the size of the markets, cost and margins for JMAR's products, failure to obtain market acceptance, current or future government regulations affecting the use of JMAR's products, the lack of availability of critical components, the degree of protection from future patents, other risks associated with the development or acquisition of new products or technologies and those risks detailed in the Company's Form 10-K for the year ended December 31, 2005 and Form 10-Q for the quarter ended September 30, 2006 filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. JMAR Technologies, Inc. does not assume any duty to publicly update or revise the material contained herein.